Amylin revenues miss estimate

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) reported 1Q09 revenues of $193.7 million, missing the Street's estimate of $204.9 million and down 2% from $197.2 million in 1Q08. Sales of diabetes drug Byet...